Arabic Arabic English English French French German German

Coenzyme Q10 can be used as a potential intervention for diminishing the disease severity and blood pressure in Ulcerative colitis patients.


Med J Islam Repub Iran. 2021 ;35:3. Epub 2021 Jan 6. PMID: 33996654

Abstract Title: 

Effects of coenzyme Q10 on health-related quality of life, clinical disease activity and blood pressure in patients with mild to moderate ulcerative colitis: a randomized clinical trial.


Ulcerative colitis (UC) is specified by a chronic mucosal inflammation that has a deleterious impact on the quality of life (QoL). Coenzyme Q10 (CoQ10) appears to influence disease activity by its obvious properties. Therefore, the current research intends to assess the impacts of CoQ10 on QoL, disease activity, and blood pressure in UC patients.This clinical trial performed on men and women with UC in 2017 who were attended the gastrointestinal center of Hazrat Rasool Akram Hospital and private clinic. Eighty-eight UC patients were randomly allocated to receive either CoQ10 (200 mg/day) or placebo for 8 weeks. The anthropometric parameters, blood pressure, inflammatory bowel disease questionnaire-32 (IBDQ-32) score, and the Simple Clinical Colitis Activity Index (SCCAI) score were measured pre and post-intervention. P-value

read more

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Why Britney feels like your BFF: Understanding social media and parasocial relationships

Next Post

‘Fortunate accident’ may yield immunity weapon against antibiotic-resistant bacteria

Related Posts